CXCL9 and neoplasm: Therefore, we stained tumor sections for Cxcl9 and Cxcl10 from untreated KPC2a-bearing mice and mice treated with αPD-L1 or CD40 agonist as such therapies may enhance IFNγ [8, 28], which induces Cxcl9/Cxcl10.